Egalet Corporation (NASDAQ:EGLT) Files An 8-K Other Events
Item 8.01 Other Events
On March29, 2017, Egalet Corporation (the Company) issued a press
release announcing that the U.S. Food and Drug Administration
does not object to the Companys distribution of promotional
materials and communications to healthcare professionals
regarding the abuse-deterrent properties of ARYMO ER (morphine
sulfate) extended-release tablets for oral use only CII via the
intranasal route, a copy of which is filed herewith as
Exhibit99.1.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits
|
Exhibit Number |
|
Description |
|
99.1 |
Press Release, dated March29, 2017 |
About Egalet Corporation (NASDAQ:EGLT)
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company’s product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company’s product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company’s product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation. Egalet Corporation (NASDAQ:EGLT) Recent Trading Information
Egalet Corporation (NASDAQ:EGLT) closed its last trading session up +0.01 at 4.84 with 98,902 shares trading hands.
